Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results

ALISO VIEJO, Calif., Feb. 7, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three months ended December 31, 2012.


Quarterly Financial Highlights

  • Total company net revenues increased to $16.5 million, representing growth of 22% versus the previous quarter
  • Gross and net NUEDEXTA® sales increased to $18.4 million and $14.9 million, respectively, representing growth of 19% and 20% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $59.3 million as of December 31, 2012.
  • "Avanir delivered another strong quarter of growth with record NUEDEXTA sales and prescriptions," said Keith A. Katkin , president and CEO of Avanir.  "In addition, the clinical team has successfully executed our plan to move our next generation asset, AVP-786, through the first stage of the phase I clinical study, with encouraging results. With demonstrated success in the AVP-786 study, we now have two promising assets in clinical development, each of which has broad potential in a number of CNS indications."

    Fiscal 2013 First Quarter Results

  • Total net revenues for the quarter ended December 31, 2012 were $16.5 million, compared with $7.2 million for the comparable quarter in fiscal 2012, representing 130% year-over-year growth. Total net revenues consist of NUEDEXTA revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $25.3 million in the first quarter of fiscal 2013, compared with $21.7 million in the comparable period in fiscal 2012.
  • Cash used in operations was $12.7 million in the first quarter of fiscal 2013.
  • Net loss for the fiscal 2013 first quarter was $12.1 million, or $0.09 per share, compared with a net loss of $15.9 million, or $0.12 per share, for the same period in fiscal 2012.
  • NUEDEXTA RevenueFor the quarter ended December 31, 2012, the company reported NUEDEXTA gross and net revenue of $18.4 million and $14.9 million respectively. First quarter fiscal 2013 NUEDEXTA net revenue increased 20% over the previous quarter.

    Cash, Cash Equivalents & Marketable SecuritiesAs of December 31, 2013 Avanir had cash, cash equivalents and investments in securities totaling $59.3 million, including cash and cash equivalents of $56.9 million and restricted investments in securities of $2.4 million.

    Business Highlights

  • The company reported its seventh consecutive quarter of record NUEDEXTA revenues and prescriptions
  • Over 13,000 cumulative patient years of exposure of NUEDEXTA in PBA across multiple neurologic conditions
  • The company successfully completed the first stage of a two-stage pharmacokinetic study with AVP-786
  • Continued clinical progress in three potential follow-on indications for AVP-923 in Alzheimer's disease, neuropathic pain, and Parkinson's disease
  • The Michael J. Fox Foundation awarded the company a grant to study AVP-923 for the treatment of levodopa-induced-dyskinesia (LID) in Parkinson's disease (PD)
  • Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2013 first quarter financial results today, February 7, 2013, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-866-783-2141 for domestic callers or +1-857-350-1600 for international callers, and entering passcode 51423033. Those interested in listening to the conference call live via the internet may do so by visiting

    About AVP-786AVP-786 is a novel compound developed through incorporation of deuterium into specific molecular positions of dextromethorphan.  The compound maintains similar pharmacology to that of dextromethorphan, but is less susceptible to metabolism by the CYP2D6 enzyme.  Avanir licensed exclusive worldwide rights to AVP-786 from Concert Pharmaceuticals, Inc. 

    About AVP-923AVP-923 is a combination of two well-characterized compounds, the active CNS ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist) plus low-dose quinidine sulfate (a CYP2D6 enzyme inhibitor), which serves to increase the bioavailability of dextromethorphan.  AVP-923 is being studied in several ongoing clinical trials including agitation in Alzheimer's disease, neuropathic pain in Multiple Sclerosis, levodopa-induced dyskinesia in Parkinson's disease, and behavioral symptoms of autism.

    About NUEDEXTANUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

    NUEDEXTA Important Safety InformationNUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

    Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

    NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

    NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

    The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

    These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at

    About Avanir Pharmaceuticals, Inc.Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit

    Avanir® and NUEDEXTA® are registered trademarks owned by Avanir Pharmaceuticals, Inc.

    ©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

    Forward Looking StatementsExcept for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

    Avanir Investor & Media Contact
    Ian Clements , PhD 
    +1 (949) 389-6700AVANIR PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETSDecember 31,September 30,20122012(unaudited)(audited)ASSETSCurrent assets:Cash and cash equivalents

    $  56,942,618$   69,778,406Trade receivables, net

    6,834,0227,231,759Inventories, net

    378,244415,475Prepaid expenses and other current assets

    4,085,9032,434,590Current portion of restricted investments in marketable securities 

    1,054,4631,054,463Total current assets

    69,295,25080,914,693Restricted investments in marketable securities, net of current portion

    1,303,9381,302,136Property and equipment, net

    1,789,1401,808,594Non-current inventories, net

    908,364908,364Other assets

    665,1591,078,009TOTAL ASSETS$  73,961,851$   86,011,796LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable, accrued expenses and other liabilities

    $  14,324,457$   15,598,666Deferred product revenues, net

    --Current portion of note payble

    4,949,9722,162,263Current portion of deferred royalty revenues

    2,557,4642,557,464Total current liabilities

    21,831,89320,318,393Accrued expenses and other liabilities, net of current portion

    869,722666,179Note Payable

    24,048,82526,698,263Deferred royalty revenues, net of current portion

    1,017,2471,491,854Total liabilities

    47,767,68749,174,689Total stockholders' equity

    26,194,16436,837,107TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY$  73,961,851$   86,011,796 


    $  14,879,262$
    5,488,763Revenues from royalties

    1,626,0101,676,120Revenue from research grant services

    15,000-Total revenues

    16,520,2727,164,883OPERATING EXPENSESCost of product sales

    838,129309,803Cost of research grant services

    9,398-Research and development

    6,648,0913,744,515Selling and marketing

    13,522,41913,782,836General and administrative

    6,538,4035,292,183Total operating expenses

    27,556,44023,129,337Loss from operations(11,036,168)(15,964,454)OTHER INCOME (EXPENSE)Interest income

    19,33114,291Interest expense

    (1,059,245)-Other, net

    -4,006Net loss and comprehensive loss$ (12,076,082)$ (15,946,157)Basic and diluted net loss per share$
    (0.12)Basic and diluted weighted average number of common shares outstanding 


    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    (Date:10/13/2015)... 2015  Graduate students across the country, with ... will soon have the opportunity to learn about ... drug discovery and development process. Eli Lilly and ... 10 leaders from academic institutions to create an ... of Drug Development."  Lilly will formally unveil the ...
    (Date:10/13/2015)... 13, 2015 anesthesia and respiratory ... billion by 2022, according to a new report by ... to their capability to resolve various environmental and lifestyle ... growth. --> anesthesia and respiratory devices market ... 2022, according to a new report by Grand View ...
    (Date:10/13/2015)... 2015   Micell Technologies , Inc. today announced ... trials of its MiStent Sirolimus Eluting Absorbable Polymer Coronary ... presented at the 27th Annual Transcatheter Cardiovascular Therapeutics ( ... , October 11-15. TCT is the world,s largest ... was designed to optimize vessel healing in patients with ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 ... ... growing natural beverage companies in the United States, today announced the release of ... Brew Coffee, and new Cranberry Cocktail Agua Fresca. All feature the unique flavor ...
    (Date:10/13/2015)... ... October 13, 2015 , ... ... ENGAGE, at HIMSS’s Patient Engagement Summit . HealthAware is a technology company ... health programs and interventions via mobile devices that provide a framework for the ...
    (Date:10/13/2015)... CA (PRWEB) , ... October 13, 2015 , ... ProText ... Pro X . With ProText Kinetic Panel, users can create energetic text animations in ... a preset into the Final Cut Pro X timeline and stylize the text. With ...
    (Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... Symposium Chairman, ... the 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. ... immediately afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key ...
    (Date:10/13/2015)... PA (PRWEB) , ... October 13, 2015 , ... In ... 2015 utility costs were 36 percent lower per square foot than in 2009. The ... actual cost of heating and cooling has decreased by eight percent. , According ...
    Breaking Medicine News(10 mins):